Claims

1. A pharmaceutical composition comprising a basic drug compound, a surfactant and a physiologically tolerable water-soluble acid characterized in that the acid:drug compound ratio is at least 1:1 by weight;

OI

comprising an acidic drug compound, a surfactant and a physiologically tolerable water-soluble base characterized in that the base:drug compound ratio is at least 1:1 by weight.

10

20

5

- 2. A composition according to claim 1 comprising a basic drug compound, a surfactant and a physiologically tolerable water-soluble acid characterized in that the acid:drug compound ratio is at least 1:1 by weight.
- 3. A composition according to claim 1 or 2 characterized in that the physical state of said composition is a solid dispersion.
 - 4. A composition according to any one of claims 1 to 3 wherein the acid is selected from the group comprising citric, fumaric, tartaric, maleic, malic, succinic, oxalic, malonic, benzoic, mandelic and ascorbic acid.
 - 5. A composition according to any one of claim 4 wherein the acid is citric acid.
- 6. A composition according to any one of claims 1 to 5 further comprising an organic polymer.
 - 7. A composition according to 6 wherein the polymer is selected from the group comprising
 - alkylcelluloses such as methylcellulose,
- hydroxyakylcelluloses such as hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose and hydroxybutylcellulose,
 - hydroxyalkyl alkylcelluloses such as hydroxyethyl methylcellulose and hydroxypropyl methylcellulose,
 - carboxyalkylcelluloses such as carboxymethylcellulose,
- alkali metal salts of carboxyalkylcelluloses such as sodium carboxymethylcellulose,
 - carboxyalkylalkylcelluloses such as carboxymethylethylcellulose.

- carboxyalkylcellulose esters,
- starches.
- pectins such as sodium carboxymethylamylopectin,
- chitin derivates such as chitosan,
- 5 heparin and heparinoids,
 - polysaccharides such as alginic acid, alkali metal and ammonium salts thereof, carrageenans, galactomannans, tragacanth, agar-agar, gum arabic, guargum and xanthan gum,
 - polyacrylic acids and the salts thereof,
- 10 polymethacrylic acids and the salts thereof, methacrylate copolymers,
 - polyvinylalcohol,

15

35

- polyvinylpyrrolidone, copolymers of polyvinylpyrrolidone with vinyl acetate,
- polyalkylene oxides such as polyethylene oxide and polypropylene oxide and copolymers of ethylene oxide and propylene oxide, e.g. poloxamers and poloxamines.
- 8. A composition according to claim 6 or 7 wherein the polymer has an apparent viscosity of 1 100 mPa.s when dissolved in a 2% aqueous solution at 20°C.
- 9. A composition according to any one of claims 6 to 8 wherein the polymer is hydroxypropylmethylcellulose.
- 10. A composition according to claim 6 or 7 that provides sustained release of the drug, characterized in that it comprises a water soluble polymer having an apparent
 viscosity of more than 1,000 mPa.s when dissolved in a 2% aqueous solution at 20°C.
 - 11. A composition according to any one of the preceding claims wherein the surfactant is an alcohol-oil transesterification product.
- 30 12. A composition according to claim 11 wherein the surfactant is cremophor RH 40 or Vitamin E TPGS.
 - 13. A composition according to any one of the preceding claims wherein the drug compound is no more than sparingly soluble in water.
 - 14. A composition according to any one of the preceding claims wherein the drug compound is selected from

15

- 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]-benzonitrile;
- 4-[[2-[(cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethylbenzonitrile;
- 4-[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile;
- 5 4-[[4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenyloxy)-2-pyrimidinyl]amino]-benzonitrile;
 - a N-oxide, an addition salt, a quaternary amine and a stereochemically isomeric form thereof.
- 15. A pharmaceutical dosage form comprising a therapeutically effective amount of a pharmaceutical composition as defined in any one of the preceding claims.
 - 16. The dosage form of claim 15 adapted for topical administration or administration into an externally voiding body cavity such as the nose, lungs, mouth, ear, stomach, rectum and vagina.
 - 17. The dosage form of claim 15 wherein said composition is filled into a standard capsule, or alternatively is mixed with bulking agents and compressed into tablets.
- 18. A pharmaceutical composition according to any one of claims 1 to 14 for use in the manufacture of a pharmaceutical dosage form for oral administration to a mammal in need of treatment, characterized in that said dosage form can be administered at any time of the day independently of the food taken in by said mammal.
- 19. Use of a pharmaceutical composition according to any one of claims 1 to 14 for the manufacture of a pharmaceutical dosage form for oral administration to a mammal in need of treatment, characterized in that said dosage form can be administered at any time of the day independently of the food taken in by said mammal.
- 20. A pharmaceutical package suitable for commercial sale comprising a container, an oral dosage form as claimed in any one of claims 15 to 17, and associated with said package written matter non-limited as to whether the dosage form can be administered with or without food.